Medicines manufacturer and supplier Morningside Pharmaceuticals has appointed a new Chief Executive Officer (CEO) and Chairman to oversee the company’s governance.
The Executive team and Group Board will be responsible for enhancing internal and external systems and processes, as well as delivering the business’ ambitious growth plans for the future.
As part of the structure changes the Leicestershire company’s Founder and Chief Executive for almost 30 years, Dr Nik Kotecha OBE, has taken on a key strategic role for the business and become Chairman of the Board.
Tim Brady, who has extensive experience of leading Business Development and Sales & Marketing in the pharmaceuticals’ sector, has become the business’ new CEO. Tim joins newly appointed Chief Operating Officer (COO) Monica Huang and Chief Financial Officer (CFO) Cliff Fung, as leader of the company’s Executive team.
Morningside’s Chairman of the Board Dr Nik Kotecha OBE said: “Morningside was founded in the 1990s through an entrepreneur’s dream of making quality healthcare an affordable and accessible reality throughout the world.
“Since then we have grown from a garage start-up to one of the Midlands’ leading life sciences businesses. None of this would have been possible without our excellent people, past and present, who have made Morningside the highly successful business it is today.
“The appointment of the Executive team is a key part of our strategic plans for continuing to grow Morningside into the future. For my part, I am very much looking forward to becoming Chairman of the Board which will play a key strategic role in guiding the business’ strategy, alongside the new Executive team.
“My passion is entrepreneurship and helping businesses grow through investing in innovation, Research & Development and exporting to international markets. To help support these core areas I will continue to take on senior regional and national advisory roles.”
Morningside’s growth plans include launching new niche generic medicines from its Research & Development (R&D) pipeline, registering products in international territories and further growing our branded and generic medicines portfolio and market share in the UK.
Tim Brady said: “Morningside is built on very solid foundations and is set for an even faster period of growth. The Leadership Team at Morningside is the best in the industry; they have proven that over the past 30 years and the challenge now is to get even better at what we do.
“All the people at Morningside are fully engaged, motivated, knowledgeable and excited about the future and this will be a hugely important advantage for us as we continue to build our reputation as a key supplier to the NHS and international markets.
“Morningside has always had an enviable product pipeline, which is going to produce some important new products in the coming months and years. An even sharper focus on speed to market for these products and stronger relations with our customers and supply chain, will mean patients and doctors will have greater choice of medicines, more quickly.”